Pfizer (NYSE:PFE) and Protalix BioTherapeutics have entered into a clinical development agreement through which Protalix will continue to administer, manage, and sponsor current ongoing clinical trials involving Elelyso. The latter currently sponsors adult and pediatric extension evaluations of Elelyso, but new clinical trials for the drug will be conducted and sponsored by Pfizer. Through the terms of the arrangement, Protalix is eligible to receive a milestone payment of $8.3 million upon the attainment of specific near-term clinical development milestones.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
AT&T (NYSE:T) formed an alliance with the Internet content delivery company Akamai (NASDAQ:AKAM) early Thursday and shares of the latter are rallying on the announcement. Through the deal’s terms, Akamai’s content delivery platform will be united with AT&T’s IP network to provide content and telecom services to companies. Specifically, Akamai’s servers will be positioned at the edge of AT&T’s IP network and in its facilities nationwide. Once deployment of Akamai’s infrastructure within AT&T’s network infrastructure is complete, the firms think that end customers should benefit from more efficient content routing and improved delivery of digital content, video and web applications. The partners will first concentrate their efforts in North America, but intend to expand worldwide within 12 months.
Verizon Communications (NYSE:VZ): AT&T and Verizon Wireless (NASDAQ:VOD) introduced coupons and daily deals that will be delivered through text messages, says GIGAom on Thursday, which added that both parties are employing location data they already own to enhance their offerings, but Verizon is also using demographic data and web browsing habits.
Don’t Miss: Pharmaceuticals: EU Courts Lay Down the Law.